Course of the study Patients will be recruited from the ENT departments of the Clermont
Ferrand, Saint-Etienne, Lyon and Grenoble university hospitals, the Lyon (Centre Léon
Bérard) and Paris (Institut Gustave Roussy) cancer centers, and the Le Puy En Velay and
Valence hospitals, all of which are accredited for cervico-facial carcinology.
A multidisciplinary consultation meeting will be required to validate the surgical
procedure.
Patients will be informed of the study by the investigating physician. After a period of
reflection and a chance to answer any questions, the patient will be included in the
study after consent has been obtained from an investigator.
The main risk factors for the development of a fistula will be recorded pre- and
intraoperatively.
Surgical criteria will be common to all investigating teams. The most important of these
will be the positioning of the LDPO collection drain opposite the pharyngeal closure
site. The drain may or may not be aspirative, depending on local habits. The concomitant
insertion of a phonatory prosthesis or a salivary bypass are not grounds for exclusion.
Post-operative care must meet precise specifications. Drainage fluids will be collected
from the drainage bottle on D2 post-op. To do this, the entire drainage bottle will be
recovered, and a new bottle will be placed over the drain if the drain is retained.
The liquid contained in the drainage bottle is then sterile-separated into different
samples directly in the patient's hospital ward:
Immunological sampling. A BD Falcon™ Conical Tubes 50 mL will be sent to the
immunology laboratory associated with the investigating center (Clermont-Ferrand
University Hospital Immunology Laboratory for the Clermont-Fd and Le Puy en Velay
sites, Lyon University Hospital Immunology Laboratory for the Grenoble, Lyon,
Valence and Lyon anti-cancer center, the immunology laboratory of the Assistance
Publique Hopitaux de Paris for the Gustave Roussy Institute and the immunology
laboratory for the Saint-Etienne center). The sample is then centrifuged at 3,000
rpm for 10 minutes at 4°C.a "high-risk" group for CPE.
Bacteriological sampling. This sample will be sent rapidly to the bacteriology
laboratory of the investigating center for standard cyto-bacteriological analysis.
For an IL 10 level on D2 post-op of less than 72pg/mL (so-called low-risk fistula group
defined from the DEFILAC pilot study), two groups of patients will be constituted:
Low-risk fistula group: OPT performed on D3 or D4 (before randomization and after IL-10
results). If TPO classified according to van la Parra ≤1, patients will be randomized
into 2 groups:
"EARLY" group: Resumption of feeding on postoperative day 3 or 4 with a liquid or
mixed diet.
"TARDIF" group: return to a mixed diet from day 7 post-op. Randomization will be
centralized, computerized with random block sizes, stratified by center and patient
age.
If the TOP shows images classified according to van la Parra>1, patients will join the
so-called high-risk CPE exploratory arm.
If IL10 levels on D2 post-op exceed 72 pg/mL (high-risk group for post-op fistula), these
patients will form a third, exploratory group, whose management will be left to the
investigator's choice, with 3 possibilities (no change in investigators' habits):
repeat surgery to clean the surgical site and repair the pharyngeal sutures,
broad-spectrum antibiotic therapy while awaiting the bacteriological results of the
cytobacteriological examination of the drainage fluid on postoperative day 2, without
repeat surgery, monitoring and no change in the investigator's routine.
Postoperative complications will then be noted and classified according to the
Clavien-Dindo classification over a period of 30 postoperative days.
The appearance of a salivary fistula at the tracheostoma will be objectified by the
appearance of saliva in the tracheostoma. The appearance of a fistula at the cervical
level will be sought either by imaging methods in the event of a cervical complication
(infection, hemorrhage) if no surgical revision is decided and surgically by loss of
sealing confirmed surgically if a revision is necessary.
The appearance of a subsequent fistula will be noted. The patient will have a final
consultation 30 days after surgery if he or she is no longer hospitalized.
The quality of life of the patients will be assessed throughout the study by completing
an anxiety questionnaire and a depression questionnaire. This assessment will be done
before surgery, on D5, D15 and D30 of surgery. Before surgery and at D5, these
questionnaires will be completed during hospitalization. At D15 and D30, the
questionnaires will be completed during hospitalization if the patient is still
hospitalized or by mail if the patient has been discharged from the surgical department
having performed the pharyngolaryngectomy procedure. The date of the start of
chemoradiotherapy will then be noted and the time between surgery and the start of this
treatment will be noted.